Home 
Medication Management
Long-Acting Risperidone Injections Administered in NYC
Among the long-acting injectable antipsychotics available today, long-acting Risperidone occupies a distinct position. It was the first second-generation antipsychotic ever formulated as a depot injection, combining the adherence advantages of long-acting delivery with the clinical benefits of an atypical antipsychotic, including greater effectiveness against the negative symptoms of schizophrenia and a reduced risk of motor side effects. That combination changed what clinicians could offer patients who needed depot therapy but were struggling with the extrapyramidal effects of first-generation options.
Good Health Psychiatric Services administers Risperidone injections in-office at our Downtown Brooklyn location, providing patients across New York City with biweekly, clinically supervised treatment as part of a personalized psychiatric care plan.
What Makes Long-Acting Risperidone Different
A Second-Generation Drug in a Depot Format
Risperidone is a second-generation (atypical) antipsychotic that blocks both dopamine D2 and serotonin 5-HT2A receptors. That dual mechanism is clinically meaningful: the added serotonergic activity contributes to better control of negative symptoms – social withdrawal, emotional flatness, reduced motivation – that first-generation antipsychotics like haloperidol and fluphenazine address less reliably. It also accounts for the lower risk of extrapyramidal side effects, which makes long-acting Risperidone a preferred option for patients who need depot therapy but do not tolerate movement-related adverse effects well.
The long-acting injectable form of Risperidone may be advantageous over long-acting first-generation antipsychotics, as it is better tolerated – with fewer extrapyramidal effects – and because long-acting injectable formulations of first-generation antipsychotics may increase the risk of depression. For patients with mood components to their illness, that last point matters considerably.
Microsphere Technology: How the Depot Works
Risperdal Consta uses a proprietary microsphere delivery system – tiny biodegradable polymer particles containing Risperidone that erode gradually after injection, releasing the drug in a sustained, controlled manner. After a single intramuscular injection, there is a small initial release of the drug, followed by a lag time of 3 weeks. The main release then starts from 3 weeks onward, is maintained from 4 to 6 weeks, and subsides by 7 weeks after the injection.
That 3-week lag is the most important pharmacokinetic fact a patient starting injectable Risperidone needs to understand. The first injection does not deliver immediate full therapeutic levels – oral antipsychotic supplementation is required during those first three weeks to maintain coverage while the microspheres begin to release. Steady-state plasma concentrations are reached after 4 injections administered every 2 weeks and are maintained for 4 to 6 weeks after the last injection. Once steady state is established, the plasma levels are notably more stable than those achieved with oral Risperidone.
Conditions Treated with Risperidone Injections
Risperidone Injection for Schizophrenia
Schizophrenia is the primary indication for which clinical evidence for long-acting risperidone injection is most extensive. In a pivotal placebo-controlled trial, patients receiving Risperdal Consta showed significant improvements on both positive and negative PANSS subscales, reflecting the atypical mechanism that first-generation depots don't replicate. For patients whose schizophrenia has responded to oral risperidone but who relapse due to missed doses, the depot removes the adherence variable without changing the drug.
Long-Acting Risperidone for Bipolar I Disorder
Risperdal Consta stands alone among the three injectables at Good Health: it is the only one FDA-approved for bipolar I disorder maintenance, as monotherapy or adjunctive to lithium or valproate. Three randomized controlled trials demonstrated that long-acting risperidone prevents relapse of mood episodes in stable bipolar I patients, addressing the core challenge of keeping a currently stable patient from cycling back into a manic or mixed episode.
Recurrent Psychosis with Adherence History
Beyond specific diagnoses, injectable risperidone is a strong option for any patient with a documented pattern of relapse tied to oral medication gaps. When the medical record shows repeated hospitalizations tracing back to non-adherence, the case for depot therapy is essentially self-evident.
The Benefits of Risperidone Injections
- Dual FDA approval: the only long-acting injectable antipsychotic at Good Health approved for both schizophrenia and bipolar I disorder maintenance, as monotherapy or alongside lithium or valproate
- Lower EPS risk: as a second-generation (atypical) antipsychotic, risperidone carries meaningfully fewer extrapyramidal side effects than haloperidol or fluphenazine depots, making it better tolerated for many patients
- Broader symptom coverage: addresses both positive symptoms (hallucinations, delusions) and negative symptoms (social withdrawal, emotional flatness, reduced motivation) more effectively than first-generation options
- Consistent plasma levels: microsphere technology delivers stable, sustained risperidone concentrations between injections, with lower peak-to-trough fluctuation than oral risperidone
- Mood episode prevention: three randomized controlled trials demonstrate that long-acting risperidone reduces the risk of manic relapse in stable bipolar I patients
- Regular care touchpoints: biweekly injections mean the clinical team has twice the scheduled contact compared to monthly injectables, supporting closer monitoring and faster response to any changes
The Evaluation and Transition Planning
Risperidone administration via depot begins with a full psychiatric evaluation covering diagnosis, symptom history, prior medication trials, and relevant medical history, including any personal or family history of QT prolongation. For patients on oral risperidone, transition involves a three-week oral overlap, a non-negotiable pharmacokinetic requirement given the microsphere lag. Patients new to Risperidone may need an oral trial first to confirm tolerability.
01
The Injection Appointment
Risperdal Consta requires refrigeration and reconstitution immediately before use — the clinical team handles preparation entirely. The injection is administered intramuscularly into the gluteal or deltoid muscle, with the full appointment running 20 to 30 minutes. Injections are scheduled every two weeks, and Good Health's same-day availability ensures a shifted schedule doesn't become a missed dose, particularly important on a biweekly regimen.
02
Monitoring and Tolerability
EPS risk is lower with Risperdal Consta than with first-generation depots, though not absent at higher doses. The primary monitoring priorities are metabolic changes – weight, glucose, lipids – along with prolactin elevation, both common considerations with second-generation antipsychotics. The clinical team reviews all parameters at regular intervals. Psychotherapy and the broader care plan continue alongside injections. Injectable Risperidone is one component of coordinated care, not a standalone solution.
03
Getting Started with Risperidone Injections in NYC
Good Health Psychiatric Services is located in Brooklyn, NY, with convenient subway access from across Brooklyn, Manhattan, and Queens. Most major insurance plans are accepted, including Aetna, Cigna, United Healthcare, Blue Cross Blue Shield, Healthfirst, MetroPlus, and Medicare. The administrative team manages prior authorization requests directly on the patient’s behalf.
New patients begin with a psychiatric intake evaluation – same-day appointments are frequently available. Patients already in care at Good Health can discuss adding a long-acting Risperidone injection at their next scheduled appointment. To schedule or ask questions, call (718) 522-3600 or request an appointment online.
FAQ
The microsphere technology in Risperdal Consta creates an unavoidable pharmacokinetic lag: the main drug release doesn’t begin until approximately three weeks after the first injection. Without oral coverage during that window, plasma levels would drop below therapeutic range. The overlap is temporary: once steady state is established after the fourth injection, the oral medication is discontinued, and the biweekly injection maintains coverage on its own.
It depends on the patient. For some, biweekly appointments feel manageable, especially with a practice like Good Health that offers flexible, same-day scheduling. The clinical upside of a shorter interval is that plasma levels remain more consistent between doses, and the care team has twice as many scheduled touchpoints for monitoring. For patients where monthly appointments are strongly preferred, haloperidol decanoate is available as an alternative.
The most meaningful differences are generation and approved indications. Risperidone is a second-generation (atypical) antipsychotic, which means lower extrapyramidal side effect risk, better coverage of negative symptoms, and, uniquely, FDA approval for bipolar I disorder maintenance. Haloperidol and fluphenazine are first-generation agents with strong efficacy for positive symptoms but more limited negative symptom coverage and higher EPS risk.
The main monitoring priorities with long-acting Risperidone are metabolic changes (weight, blood glucose, lipids), prolactin elevation, and, at higher doses, QT interval. Extrapyramidal effects are less common than with first-generation depots, but not absent. The care team reviews all of these at regular visits and adjusts the plan if needed.
Yes, and this is one of the FDA-approved use cases. Risperdal Consta is indicated for bipolar I maintenance as an adjunct to lithium or valproate, not just as monotherapy. The prescribing clinician reviews the full medication list before starting the depot to check for interactions and ensure the combined regimen is appropriate.